Exactech Announces Successful First Surgeries with New Revision Knee System
September 30 2015 - 12:50PM
Business Wire
Enhances Focus on Revision Arthroplasty with
Pilot Launch of Three New Revision Systems in Fourth Quarter
Exactech, Inc. (Nasdaq: EXAC), a worldwide developer and
producer of bone and joint restoration products, announced today
the successful first surgeries performed with its new revision knee
system. Designed to provide a reproducible surgical technique for
treating complex revision total knee replacement patients, the
system includes a comprehensive implant offering and ergonomically
designed instrumentation. Pilot launch is scheduled through the
remainder of the year with full market availability in the United
States in 2016.
Orthopaedic surgeons Bernard Stulberg, MD, of St. Vincent
Charity Medical Center in Cleveland, Ohio, and Geoffrey Westrich,
MD, of Hospital for Special Surgery in New York, NY performed the
first cases using the knee system during the past week.
"I was honored and pleased to be the first to use the new
instruments and devices for revision of a failed knee replacement,”
Dr. Stulberg said. “The implant provided excellent early stability
and kinematics, and allowed my patient to be discharged to home
within two days. The instruments were intuitive, comfortable to use
and allowed for a straightforward and accurate approach to
assessing bone loss, and for re-establishing proper implant
position, alignment and stability. This was a satisfying experience
that I believe many surgeons will be able to share, as this
innovative new implant and instrument system helps them to address
the myriad of problems encountered in revision total knee
replacement.”
The revision knee system addresses Exactech’s knee design
philosophy of delivering “performance over time” in a streamlined
procedure. The evolutionary design incorporates clinically
recognized, patented designs and proprietary net compression molded
polyethylene. Combined with modern, user friendly instrumentation,
the revision knee system is designed for operating room efficiency
and reproducible outcomes, case after case.
“In developing Exactech’s new revision knee system, the team
focused on reproducibility and efficiency while also leveraging
proven design elements that have delivered excellent long-term
clinical outcomes,” Dr. Westrich said. “The first case was a great
success.”
According to Exactech CEO David Petty, the knee system is one of
three new revision implant and instrumentation systems that are
making their clinical debut. The company is also piloting its new
revision hip stem and a shoulder humeral reconstruction prosthesis.
“We are reaffirming our commitment to revision arthroplasty,” Petty
said. “It is our goal to deliver patient-driven solutions that
allow surgeons to provide a wide continuum of care. Clinical use of
this knee system is the culmination of years of collaboration with
world-renowned revision total knee surgery experts.”
Exactech worked closely with a design team of experienced
revision knee surgeons to develop this revision system: Bernard
Stulberg, MD, St. Vincent Charity Medical Center; Geoffrey
Westrich, MD, Hospital for Special Surgery; Daniel C. Allison, MD,
Cedars-Sinai Medical Center; James Huddleston, MD, Stanford
Medicine; Richard Parkinson, MB ChB, FRCS, Spire Murrayfield
Hospital Wirral, United Kingdom.
The new Exactech revision knee system is indicated for use in
skeletally mature patients undergoing surgery for total knee
replacement due to osteoarthritis, osteonecrosis, rheumatoid
arthritis and/or post-traumatic degenerative problems; this device
is also indicated for revision of failed previous reconstruction
where sufficient bone stock and soft tissue integrity are
present.
About Exactech Knee
The Exactech knee system combines clinically proven implants
with personalized surgical workflows for reproducible outcomes,
case after case. With a design developing for more than four
decades and excellent clinical and laboratory results, surgeons can
have every confidence in a system that delivers “performance over
time”.
About Exactech
Based in Gainesville, Fla., Exactech develops and markets
orthopaedic implant devices, related surgical instruments and
biologic materials and services to hospitals and physicians. The
company manufactures many of its orthopaedic devices at its
Gainesville facility. Exactech’s orthopaedic products are used in
the restoration of bones and joints that have deteriorated as a
result of injury or diseases such as arthritis. Exactech markets
its products in the United States, in addition to more than 30
markets in Europe, Latin America, Asia and the Pacific. Additional
information about Exactech, Inc. can be found at
http://www.exac.com. Copies of Exactech’s press releases, SEC
filings, current price quotes and other valuable information for
investors may be found at http://www.exac.com and
http://www.hawkassociates.com.
An investment profile on Exactech may be found at
http://www.hawkassociates.com/profile/exac.cfm. To receive future
releases in e-mail alerts, sign up at
http://www.hawkassociates.com/about/alert.
This release contains various forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Exchange Act of 1934, which represent
the company’s expectations or beliefs concerning future events of
the company’s financial performance. These forward-looking
statements are further qualified by important factors that could
cause actual results to differ materially from those in the
forward-looking statements. These factors include the effect of
competitive pricing, the company’s dependence on the ability of
third party manufacturers to produce components on a basis which is
cost-effective to the company, market acceptance of the company’s
products and the effects of government regulation. Results actually
achieved may differ materially from expected results included in
these statements.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20150930006500/en/
Exactech, Inc.Investor contactsJody Phillips,
352-377-1140Executive Vice President of Finance &Chief
Financial OfficerorHawk AssociatesJulie Marshall or Frank Hawkins,
305-451-1888E-mail: EXAC@hawkassociates.comorMedia contactPriscilla
Bennett, 352-377-1140Vice President, Corporate & Marketing
Communication
Exactech, Inc. (delisted) (NASDAQ:EXAC)
Historical Stock Chart
From Mar 2024 to Apr 2024
Exactech, Inc. (delisted) (NASDAQ:EXAC)
Historical Stock Chart
From Apr 2023 to Apr 2024